2011
Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients
Chan KE, Ikizler TA, Gamboa JL, Yu C, Hakim RM, Brown NJ. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney International 2011, 80: 978-985. PMID: 21775975, PMCID: PMC3656595, DOI: 10.1038/ki.2011.228.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCardiovascular DiseasesDrug Therapy, CombinationFemaleHumansHypertensionKaplan-Meier EstimateKidney Failure, ChronicLogistic ModelsMaleMiddle AgedPropensity ScoreProportional Hazards ModelsRenal DialysisRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTime FactorsTreatment OutcomeUnited StatesConceptsAngiotensin receptor blockersAntihypertensive medicationsARB therapyCardiovascular deathChronic hemodialysisCardiovascular mortalityHazard ratioHemodialysis patientsRisk factorsBaseline cardiovascular risk factorsAngiotensin-converting enzyme inhibitionLarge dialysis providerCardiovascular risk factorsChronic hemodialysis patientsKaplan-Meier methodMortality hazard ratioAntihypertensive therapyReceptor blockersAntihypertensive agentsCox regressionCerebrovascular mortalityClinical trialsTreatment weightingObservational studyACEI
2005
Angiotensin-Converting Enzyme Inhibition Increases Basal Vascular Tissue Plasminogen Activator Release in Women But Not in Men
Pretorius M, Luther JM, Murphey LJ, Vaughan DE, Brown NJ. Angiotensin-Converting Enzyme Inhibition Increases Basal Vascular Tissue Plasminogen Activator Release in Women But Not in Men. Arteriosclerosis Thrombosis And Vascular Biology 2005, 25: 2435-2440. PMID: 16166566, DOI: 10.1161/01.atv.0000186185.13977.94.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAngiotensin-Converting Enzyme InhibitorsBlood PressureBradykininEnalaprilatFemaleHumansLuteal PhaseMaleMethacholine ChlorideMiddle AgedNitroprussideParasympathomimeticsPeptide FragmentsPeptidyl-Dipeptidase APostmenopausePremenopauseRegional Blood FlowSex CharacteristicsTissue Plasminogen ActivatorVasodilator AgentsConceptsT-PA releaseForearm blood flowBasal t-PA releaseNet t-PA releaseTissue plasminogen activator releasePostmenopausal womenPlasminogen activator releaseOlder menPremenopausal womenMenopausal statusActivator releaseIntra-arterial enalaprilatEffect of ACEIEndogenous bradykininHormone replacementExogenous bradykininBlood flowACEIBradykininEnalaprilatWomenYoung menMenEnzyme inhibitionRelease
2002
Dipeptidyl Peptidase IV Activity in Patients With ACE-Inhibitor-Associated Angioedema
Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl Peptidase IV Activity in Patients With ACE-Inhibitor-Associated Angioedema. Hypertension 2002, 39: 460-464. PMID: 11882590, DOI: 10.1161/hy0202.103054.Peer-Reviewed Original ResearchConceptsDPPIV activityHypertensive volunteersHypertensive subjectsRemote historyAcute ACE inhibitionSerum DPPIV activityUntreated hypertensive controlsUntreated hypertensive subjectsMetabolism of bradykininDipeptidyl peptidase IV activityAcute ACEIChronic ACEiPeptidase IV activityCorticosteroid treatmentHypertensive controlsHypertensive patientsNormotensive volunteersNormotensive controlsACE inhibitorsACE inhibitionSubstance PBradykinin degradationAssociated angioedemaACEIAngioedema
1999
Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema
Blais C, Rouleau J, Brown N, Lepage Y, Spence D, Munoz C, Friborg J, Geadah D, Gervais N, Adam A. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999, 43: 293-302. PMID: 10596866, DOI: 10.1016/s0162-3109(99)00133-2.Peer-Reviewed Original ResearchConceptsDes-Arg9AE patientsC subjectsLife-threatening adverse reactionsEnzyme (ACE) inhibitor-associated angioedemaMetabolism of bradykininLocal inflammatory reactionEnzyme defectPreincubation of seraBK metabolismSensitive enzyme immunoassayB1 agonistSerum metabolismAdverse reactionsControl subjectsInflammatory reactionACEIAngioedemaAbnormal metabolismPatientsEnzyme inhibitorsSynthetic bradykininControl seraBradykininEnzyme immunoassay
1997
Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin
Brown N, Nadeau J, Vaughan D. Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin. Thrombosis And Haemostasis 1997, 77: 522-525. PMID: 9066005, DOI: 10.1055/s-0038-1656000.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBradykininCaptoprilFemaleHumansHypertensionIsoquinolinesMalePlasminogen Activator Inhibitor 1QuinaprilRandomized Controlled Trials as TopicTetrahydroisoquinolinesTissue Plasminogen ActivatorConceptsT-PA antigen levelsTissue-type plasminogen activatorMean arterial pressureT-PA levelsAntigen levelsPAI-1 antigen levelsInfusion of bradykininSympathetic nervous systemEffect of bradykininTissue-type plasminogen activator secretionHypertensive patientsHemodynamic effectsArterial pressurePlasminogen activator secretionAngiotensin IIAnimal modelsPotent stimulusNervous systemPAI-1ACEIBradykininBradykinin resultsSelective stimulationPlasminogen activatorSignificant decrease